Singaporean-based ASLAN Pharmaceuticals has raised $42 million in an initial public offering (IPO) of 6,000,000 American Depositary Shares, each representing five ordinary shares.
Leerink Partners and Piper Jaffray acted as joint book-running managers for the offering. BTIG, H.C. Wainwright & Co., and CLSA acted as co-managers for the offering.
The IPO marks the first Taipei Exchange-listed company to go public in the U.S.
The All-dielectric self-supporting now trade on the Nasdaq Global Market under the symbol ASLN and the ordinary shares have traded on the Taipei Exchange since the second quarter of 2017.